Today: 7 February 2026
Subscribe
Browse Category

Pharma News News 30 November 2025 - 8 December 2025

Natco Pharma Share Price Today (8 December 2025): Q2 Results, Adcock Ingram Deal and 2026 Stock Outlook

Natco Pharma Share Price Today (8 December 2025): Q2 Results, Adcock Ingram Deal and 2026 Stock Outlook

Natco Pharma Limited (NSE: NATCOPHARM) is back in the spotlight as the stock trades lower on 8 December 2025 even while the company closes a landmark acquisition in South Africa and navigates life after its blockbuster Revlimid (lenalidomide) windfall. Around late morning on Monday, 8 December, Natco Pharma was trading near ₹908–₹910 on the NSE, down roughly 2.5–3% from Friday’s close of ₹933.60. The stock has moved in a wide intraday band of about ₹904–946 and remains roughly 40% below its 52‑week high of ₹1,505, despite a 6–8% gain over the past week.mint+2Moneycontrol+2 Fundamentals remain solid—low leverage, strong profitability and
8 December 2025
····
Bristol Myers Squibb (BMY) Stock Update – 7 December 2025: Alzheimer’s Trial Twist, ASH 2025 Pipeline Data and a $6.7 Billion Lawsuit

Bristol Myers Squibb (BMY) Stock Update – 7 December 2025: Alzheimer’s Trial Twist, ASH 2025 Pipeline Data and a $6.7 Billion Lawsuit

Bristol Myers Squibb (NYSE: BMY) has packed a lot into the first week of December 2025 – from a surprise update on a key Alzheimer’s drug trial to major hematology data at ASH 2025 and a legal setback over its Celgene acquisition. All of this is landing on a stock that has finally bounced after years of underperformance but still trades as a high‑yield value name. As of the market close on Friday, 5 December 2025, BMY shares were at $52.15, with after‑hours trading around $52.05, giving the company a market capitalization of roughly $106 billion. The stock’s 52‑week range
7 December 2025
·····
RXRX Stock Today: Insider Selling, CEO Transition and Trial Catalyst Shape Recursion Pharmaceuticals’ Outlook (December 2025)

RXRX Stock Today: Insider Selling, CEO Transition and Trial Catalyst Shape Recursion Pharmaceuticals’ Outlook (December 2025)

Recursion Pharmaceuticals (NASDAQ: RXRX), one of the highest‑profile AI‑driven drug discovery names, is back under the microscope. As of the December 5, 2025 close, RXRX stock traded around $4.71, giving the company a market capitalization of roughly $2.5 billion and placing shares close to the bottom of their 52‑week range between about $3.79 and $12.36.StockAnalysis Shares are down roughly 35% in 2025 and have fallen about 88% from their record highs, underscoring how brutal the reset has been for speculative AI/biotech names after the initial hype wave.Intellectia AI+1 Yet the story is far from over. In early December 2025, three
7 December 2025
·····
Ocular Therapeutix (OCUL) Stock News Today: Price, Forecast and Analysis as AXPAXLI NDA Plan Emerges

Ocular Therapeutix (OCUL) Stock News Today: Price, Forecast and Analysis as AXPAXLI NDA Plan Emerges

As of the close on Friday, December 5, 2025, Ocular Therapeutix, Inc. (NASDAQ: OCUL) finished regular trading at $12.58 per share, up about 1.2% on the day, with after‑hours quotes on some platforms briefly touching the $14 area. StockAnalysis+1 The move caps a strong week: on Thursday the stock jumped roughly 12.3% to around $12.87, well above its recent averages, as traders responded to a new regulatory strategy for its lead retina drug AXPAXLI and fresh analyst commentary. MarketBeat+1 At the same time, OCUL remains firmly in “story stock” biotech territory: still loss‑making, heavily dependent on its late‑stage pipeline, but
6 December 2025
·····
Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon Ltd. (NASDAQ: PLRZ) has gone from obscure micro‑cap to headline‑grabbing biotech in just two trading days. On December 4, 2025, the stock was changing hands in the mid‑teens, more than doubling from the prior close of $7.09, with intraday swings between roughly $12.5 and $18.2 and volume near 26 million shares – over 20× its recent average. MarketBeat+1 Behind this violent move are two concrete catalysts: At the same time, quantitative services and technical models are sending mixed—and often cautious—signals, with several “Strong Sell” ratings even as momentum screens flash “Buy” or “Strong Buy.” TipRanks+4Danelfin AI+4TradingView+4 This article walks
4 December 2025
·····
CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors

CRISPR Therapeutics Stock (CRSP) in December 2025: Price, Forecast, CASGEVY Growth and Takeover Rumors

Updated: December 4, 2025 Key takeaways CRISPR Therapeutics stock today: price, volatility and positioning As of pre‑market trading on December 4, 2025, CRISPR Therapeutics AG (NASDAQ: CRSP) is changing hands at roughly $56, just above Wednesday’s close of $55.99, after jumping 8.5% in the last regular session. stockinvest.us+1 Over the past 12 months, CRSP has traded between about $30.04 and $78.48, leaving today’s price squarely in the middle of its 52‑week range. stockinvest.us A few quick stats: Technically, services like StockInvest.us classify CRSP as a “hold/accumulate” with a wide expected three‑month range (~$43–$64), while Intellectia’s model calls it a “Strong
4 December 2025
·····
Capricor Therapeutics (CAPR) Soars After HOPE‑3 Win: Latest News, Analyst Targets and Stock Forecast as of December 4, 2025

Capricor Therapeutics (CAPR) Soars After HOPE‑3 Win: Latest News, Analyst Targets and Stock Forecast as of December 4, 2025

Updated: December 4, 2025 – mid‑day U.S. trading Capricor Therapeutics, Inc. (NASDAQ: CAPR) has just pulled off the kind of move small‑cap biotech traders dream about and risk managers lose sleep over. After releasing decisive Phase 3 data for its Duchenne muscular dystrophy (DMD) cell therapy Deramiocel, the stock has exploded several hundred percent in barely two trading sessions and is now hovering around $29.96 per share. The HOPE‑3 trial didn’t just “meet endpoints” in a boring, incremental way. It showed a 54% slowing of upper‑limb functional decline and 91% preservation of heart function versus placebo – in a disease
4 December 2025
·····
GSK Stock Outlook December 2025: Q3 Beat, Buybacks and Big FDA Decisions Shape 2026 Forecasts

GSK Stock Outlook December 2025: Q3 Beat, Buybacks and Big FDA Decisions Shape 2026 Forecasts

As of December 3, 2025, GSK plc (LSE:GSK, NYSE:GSK) is trading near multi‑year highs after a year of earnings beats, a revived oncology franchise, heavy share buybacks and an unusually busy FDA calendar for December. At the same time, analysts are still only lukewarm on the stock, and long‑term growth expectations lag management’s ambitions. This is a deep dive into where GSK stock stands today, what’s driving the rally, and what current news and forecasts are signalling about 2026 and beyond. GSK share price today and 2025 performance On the NYSE, GSK’s U.S. ADR is trading around $48.27 in early
3 December 2025
······
Natco Pharma Share Price Today (2 December 2025): Rating Reaffirmed, USFDA Update, South Africa Deal and 2026 Stock Forecast

Natco Pharma Share Price Today (2 December 2025): Rating Reaffirmed, USFDA Update, South Africa Deal and 2026 Stock Forecast

Natco Pharma has had a busy few months: a big overseas acquisition in South Africa, a fresh USFDA inspection with Form 483 observations, strong-but-normalising earnings, and a credit-rating reaffirmation that reassured debt markets. The share price is finally stabilising after a brutal fall earlier in 2025, but the market is still arguing about what the stock is really worth. Below is a detailed, news-style rundown of where Natco Pharma Limited stands as of 2 December 2025, and how analysts and models are currently reading the stock. Natco Pharma share price today: rebound, but still far below 52‑week high As of
2 December 2025
····
Eli Lilly (LLY) Stock on December 1, 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Outlook

Eli Lilly (LLY) Stock on December 1, 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Outlook

As of December 1, 2025, Eli Lilly and Company (NYSE: LLY) is trading around $1,075 per share, giving the drugmaker a market capitalization of roughly $1.0–1.02 trillion and cementing its status as the first pharmaceutical company to enter the trillion‑dollar club. MarketBeat+1 But today’s story is not just about the share price. Fresh Zepbound price cuts, new World Health Organization (WHO) guidance on GLP‑1 obesity drugs, and ongoing debate over valuation vs. growth are shaping how investors look at Eli Lilly stock heading into 2026. Below is a detailed, news‑driven look at LLY stock on December 1, 2025, including the
1 December 2025
·····
Natco Pharma Share Price Today (1 December 2025): Q2 Results, USFDA Update, Adcock Ingram Deal & 2026 Forecast

Natco Pharma Share Price Today (1 December 2025): Q2 Results, USFDA Update, Adcock Ingram Deal & 2026 Forecast

Mumbai, 1 December 2025 — Natco Pharma Limited (NSE: NATCOPHARM, BSE: 524816) is back in the spotlight. The stock is seeing heavy trading, fresh institutional interest and a sharp intraday bounce, even as investors digest softer Q2 FY26 earnings, a recent USFDA inspection in Chennai and a large acquisition in South Africa. Natco Pharma share price today: sharp bounce with heavy volumes As of around 11:05 am IST on 1 December 2025, Natco Pharma was quoted near ₹921 on the NSE, up almost 5% for the day. The stock has traded in a day range of ₹880–923, against a 52‑week
1 December 2025
····
AbbVie Inc (ABBV) Stock on November 30, 2025: Analyst Downgrade, FDA Wins and Dividend Strength

AbbVie Inc (ABBV) Stock on November 30, 2025: Analyst Downgrade, FDA Wins and Dividend Strength

AbbVie Inc. (NYSE: ABBV) heads into the final month of 2025 with a mixed but generally constructive backdrop for shareholders. The stock is trading in the mid‑$220s per share — around $227 — implying a market capitalization of roughly $400 billion and a dividend yield in the low‑3% range. StockAnalysis+1 Year to date, AbbVie stock is up more than 30%, comfortably ahead of the broader market, even after a modest pullback in recent sessions. Tokenist+1 At the same time, fresh Medicare pricing pressure, a high headline price-to-earnings ratio and the latest analyst rating change on November 30 are giving investors
30 November 2025
·····
1 … 5 6 7 8 9 … 11

Stock Market Today

Lloyds share price steadies after buyback update and BoE rate jitters — what to watch next week

Lloyds share price steadies after buyback update and BoE rate jitters — what to watch next week

7 February 2026
Lloyds shares closed up 0.9% at 106.75 pence Friday after the bank announced fresh buybacks totaling 17 million shares over two days, all to be cancelled. The stock rebounded from a 5.6% drop Thursday as traders adjusted UK rate-cut bets. About 121 million Lloyds shares changed hands. Investors await the bank’s annual report on February 18 and the next Bank of England decision March 19.
Vodafone shares steady up after Q3 wobble — Germany, buyback and next results now set the tone

Vodafone shares steady up after Q3 wobble — Germany, buyback and next results now set the tone

7 February 2026
Vodafone shares rose 1.47% to 110.60p Friday, recovering part of Thursday’s 4.68% drop after a Q3 update. Group revenue climbed 6.5% to €10.5 billion, but Germany’s 0.7% service revenue growth missed some forecasts. Vodafone launched a new €500 million buyback tranche, bringing total buybacks since May to €3.5 billion. Investors remain focused on Germany’s pace and cash flow execution.
NatWest Group stock: buyback filing and Rightmove mortgage deal set up a busy week

NatWest Group stock: buyback filing and Rightmove mortgage deal set up a busy week

7 February 2026
NatWest shares closed up 1.45% at 659.4 pence Friday, buoyed by a buyback of 797,428 shares and a new digital mortgage deal with Rightmove. The Bank of England held rates at 3.75% but signaled possible cuts, with markets pricing in two reductions for 2026. NatWest plans to expand its Accelerator community to 50,000 members by 2026. Annual results are due Feb. 13.
Unilever share price holds at 5,250p as results week looms — what investors watch next

Unilever share price holds at 5,250p as results week looms — what investors watch next

7 February 2026
Unilever shares closed flat at 5,250p in London Friday, underperforming the FTSE 100’s 0.6% gain. The company issued 4.2 million new shares for employee plans, bringing total shares to over 2.18 billion. Investors await Q4 and full-year results on Feb. 12, with analyst consensus pointing to 3.9% Q4 sales growth. Unilever’s U.S. ADR rose 0.8% to $72.12.
Go toTop